Milestone Pharmaceuticals Inc. (MIST): Price and Financial Metrics

Milestone Pharmaceuticals Inc. (MIST)

Today's Latest Price: $6.84 USD

0.14 (2.09%)

Updated Dec 4 4:00pm

Add MIST to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MIST Stock Price Chart Interactive Chart >

Price chart for MIST

MIST Price/Volume Stats

Current price $6.84 52-week high $23.25
Prev. close $6.70 52-week low $1.69
Day low $6.52 Volume 78,000
Day high $6.95 Avg. volume 1,991,590
50-day MA $6.65 Dividend yield N/A
200-day MA $6.69 Market Cap 203.99M

Milestone Pharmaceuticals Inc. (MIST) Company Bio

Milestone Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. It designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.

MIST Latest News Stream

Event/Time News Detail
Loading, please wait...

MIST Latest Social Stream

Loading social stream, please wait...

View Full MIST Social Stream

Latest MIST News From Around the Web

Below are the latest news stories about Milestone Pharmaceuticals Inc that investors may wish to consider to help them evaluate MIST as an investment opportunity.

Milestone Pharma launches 6.7M-share secondary offering

Milestone Pharmaceuticals (MIST) has filed a prospectus for ~6.7M shares of common stock offered by selling shareholders, issuable upon exercise of pre-funded warrants.The company will not receive any proceeds from the sale of shares by the selling stockholders....

Seeking Alpha | August 21, 2020

It's Risky, but Milestone Pharmaceuticals Holds Promise Among Tiny Biotechs

When a biotech firm focuses its efforts on one disease and one drug, the stakes are high. Still, the payoff could be huge with MIST stock.

InvestorPlace | August 19, 2020

Milestone Pharmaceuticals EPS misses by $0.06

Milestone Pharmaceuticals (MIST): Q2 GAAP EPS of -$0.53 misses by $ equivalents, and short-term investments of $85.4M.Press Release...

Seeking Alpha | August 12, 2020

Oppenheimer: These 3 “Strong Buy” Stocks Have Over 50% Upside Potential

Despite COVID-19’s devastating impact on the economy, Oppenheimer’s Chief Investment Strategist John Stoltzfus remains overweight on U.S. equities, and is more bullish on cyclical sectors versus defensive sectors. As for the legitimate concerns about the virus’ re-emergence, Stolzfus argues investors should “consider the reopening setbacks as just that and not something that is permanent.” "In the past week along with legitimate concerns about the recent resurgences of Covid-19 stateside and abroad there was also a resurgence of the “life will never be the same” kind of worry creeping into the theme du jour. We don’t attribute much value to the latter worry as collaborative efforts by scientists across the globe continue at record pace to pursue vaccines to stem the spread of the v...

Yahoo | July 31, 2020

76 Biggest Movers From Yesterday

Gainers Milestone Pharmaceuticals Inc (NASDAQ: MIST) shares climbed 166.8% to close at $8.91 on Thursday. Following recent interactions with the FDA …

Benzinga | July 24, 2020

Read More 'MIST' Stories Here

MIST Price Returns

1-mo 11.95%
3-mo -11.74%
6-mo 82.89%
1-year -57.99%
3-year N/A
5-year N/A
YTD -57.28%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7209 seconds.